PMID- 22287471
OWN - NLM
STAT- MEDLINE
DCOM- 20120604
LR  - 20181201
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 1
IP  - 5
DP  - 2011 Sep-Oct
TI  - Desensitizing mice to ovalbumin through subcutaneous microsphere immunotherapy 
      (SMITH).
PG  - 390-5
LID - 10.1002/alr.20074 [doi]
AB  - BACKGROUND: We investigated whether subcutaneously-injected, biodegradable, poly 
      (D,L-lactic-co-glycolic) acid (PLGA) microspheres loaded with ovalbumin (OVA) 
      were able to down-regulate the T helper 2 (TH2) response in mice that were 
      sensitized to this protein, and whether this response was dose-dependent. 
      METHODS: PLGA microspheres were created using a double emulsion technique. Female 
      BALB/c mice were sensitized to OVA and then assigned to receive subcutaneous 
      microsphere immunotherapy (SMITH) using either blank microspheres (n = 4), 
      low-dose OVA-loaded microspheres (n = 5), or high-dose OVA-loaded microspheres (n 
      = 5). Antigen-specific immunoglobulin E (IgE) in serum was measured at day 0 
      (prior to sensitization), day 14 (prior to immunization), and days 28 and 42 
      (after immunization). RESULTS: All mice were successfully sensitized to OVA. In 
      the group receiving blank microspheres, there was a continual rise in 
      antigen-specific IgE from Day 14 to Day 42, which was statistically significant. 
      In the group receiving low-dose OVA-loaded microspheres, there was a 
      statistically significant drop in the antigen-specific IgE levels from Day 14 to 
      Day 28, but overall no significant change in IgE level when looking at the Day 14 
      to Day 42 interval. A similar pattern of antibody level changes was seen in the 
      group receiving high-dose OVA-loaded microspheres, but the decrease from Day 14 
      to Day 28 was not statistically significant. CONCLUSION: Our data suggest that 
      SMITH has the ability to downregulate the production of antigen-specific IgE in a 
      food allergy model, and this observation in our study was not dose-dependent. Its 
      potential use in the treatment of IgE-mediated allergic disease warrants further 
      investigation.
CI  - Copyright (c) 2011 American Rhinologic Society-American Academy of Otolaryngic 
      Allergy, LLC.
FAU - Reisacher, William R
AU  - Reisacher WR
AD  - Department of Otorhinolaryngology, Weill Cornell Medical College, New York, NY, 
      USA. wir2011@med.cornell.edu
FAU - Liotta, Dara
AU  - Liotta D
FAU - Yazdi, Sara
AU  - Yazdi S
FAU - Putnam, David
AU  - Putnam D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110606
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Biocompatible Materials)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Biocompatible Materials/pharmacology
MH  - Desensitization, Immunologic/*methods
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Feasibility Studies
MH  - Female
MH  - Immunoglobulin E/*blood
MH  - Lactic Acid/pharmacology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Microspheres
MH  - Ovalbumin/*immunology
MH  - Pilot Projects
MH  - Polyglycolic Acid/pharmacology
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - T-Lymphocytes, Helper-Inducer/*metabolism
EDAT- 2012/01/31 06:00
MHDA- 2012/06/05 06:00
CRDT- 2012/01/31 06:00
PHST- 2010/11/05 00:00 [received]
PHST- 2011/02/03 00:00 [revised]
PHST- 2011/05/01 00:00 [accepted]
PHST- 2012/01/31 06:00 [entrez]
PHST- 2012/01/31 06:00 [pubmed]
PHST- 2012/06/05 06:00 [medline]
AID - 10.1002/alr.20074 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2011 Sep-Oct;1(5):390-5. doi: 10.1002/alr.20074. Epub 
      2011 Jun 6.